{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:14:01Z","timestamp":1791645241966,"version":"4.3.4"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>BACKGROUND:<\/jats:title>\n            <jats:p>Animal studies indicate that liraglutide is not recommended for managing gestational diabetes mellitus and obesity during pregnancy due to potential developmental toxicity. We report a case of liraglutide exposure during the first trimester in a woman with obesity taking the maximum dose (3 mg subcutaneously daily), along with a neurodevelopmental assessment of the child conducted 14 months postpartum. Additionally, this report includes a literature review on the teratogenic effects of anti-obesity medications.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CASE:<\/jats:title>\n            <jats:p>A 29-year-old woman, gravida 9 para 6, with obesity and no history of chronic diseases was admitted at 7 weeks of gestation after taking liraglutide 3 mg\/d subcutaneously for weight loss for 8 months. Liraglutide was immediately discontinued, and routine antenatal management was initiated. The patient underwent cesarean delivery at 37 weeks of gestation; the neonate had low birth weight but was otherwise healthy. Follow-up during 14 months postpartum indicated appropriate childhood weight gain and normal neurodevelopmental assessment for age.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION:<\/jats:title>\n            <jats:p>This case report demonstrates a normal pregnancy outcome after exposure to a high dose of liraglutide during the first 7 weeks of pregnancy, apart from a low birth weight. These findings enhance the limited understanding of liraglutide exposure during pregnancy. More studies are required to establish a causal relationship between neonatal weight and liraglutide exposure. Longitudinal follow-up of children beyond 14 months is essential to evaluate growth and neurodevelopmental outcomes and assess any long-term teratogenic effects from anti-obesity drugs.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/og9.0000000000000077","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T21:05:12Z","timestamp":1744319112000},"page":"e077","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Exposure to High-Dose Liraglutide in a Pregnant Woman With Obesity"],"prefix":"10.1097","volume":"2","author":[{"given":"Dina","family":"Abushanab","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haseebur Rahman","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Palli Valappila","family":"Abdul Rouf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binny","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoud","family":"Al-Badriyeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wessam","family":"Elkassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Al-Mohannadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Hanssens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shabina","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaban","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moza","family":"Al Hail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,4]]},"reference":[{"key":"R1-20250410","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"R2-20250410","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R3-20250410","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/S0140-6736(10)60888-4","article-title":"Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"376","author":"Greenway","year":"2010","journal-title":"Lancet (London, England)"},{"key":"R4-20250410","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/oby.20309","article-title":"A randomized, phase 3 trial of naltrexone SR\/bupropion SR on weight and obesity-related risk factors (COR-II)","volume":"21","author":"Apovian","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"R5-20250410","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/oby.2010.147","article-title":"Weight loss with naltrexone SR\/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial","volume":"19","author":"Wadden","year":"2011","journal-title":"Obesity (Silver Spring)"},{"key":"R6-20250410","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"key":"R7-20250410","doi-asserted-by":"crossref","first-page":"669","DOI":"10.3390\/medicina57070669","article-title":"A 2021 update on the use of liraglutide in the modern treatment of 'diabesity': a narrative review","volume":"57","author":"Tilinca","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"R8-20250410","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet (London, England)"},{"key":"R10-20250410","doi-asserted-by":"crossref","first-page":"e571","DOI":"10.1016\/j.orcp.2013.11.008","article-title":"Antiobesity drugs in early pregnancy and congenital malformations in the offspring","volume":"8","author":"K\u00e4ll\u00e9n","year":"2014","journal-title":"Obes Res Clin Pract"},{"key":"R11-20250410","first-page":"e6170","article-title":"Phentermine use during first and second trimesters associated with fetal stroke","volume":"11","author":"D'Adesky","year":"2019","journal-title":"Cureus"},{"key":"R12-20250410","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD010224.pub2","article-title":"Monotherapy treatment of epilepsy in pregnancy: congenital malformation outcomes in the child","author":"Weston","year":"2016","journal-title":"The Cochrane Database of Systematic Reviews"},{"key":"R13-20250410","doi-asserted-by":"crossref","first-page":"980","DOI":"10.3109\/00016349.2010.485632","article-title":"Fetal cardiac arrhythmia during bupropion use","volume":"89","author":"Leventhal","year":"2010","journal-title":"Acta Obstet Gynecol Scand"},{"key":"R14-20250410","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1212\/01.wnl.0000318293.28278.33","article-title":"Topiramate in pregnancy: preliminary experience from the UK epilepsy and pregnancy register","volume":"71","author":"Hunt","year":"2008","journal-title":"Neurology"},{"key":"R15-20250410","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/0002-9378(77)90645-7","article-title":"Effects of antenatal exposure to anorectic drugs","volume":"129","author":"Milkovich","year":"1977","journal-title":"Am J Obstet Gynecol"},{"key":"R16-20250410","doi-asserted-by":"crossref","first-page":"e083550","DOI":"10.1136\/bmjopen-2023-083550","article-title":"Use of GLP1 receptor agonists in early pregnancy and reproductive safety: a multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services","volume":"14","author":"Dao","year":"2024","journal-title":"BMJ Open"},{"issue":"suppl 1","key":"R17-20250410","doi-asserted-by":"crossref","first-page":"deae108.041","DOI":"10.1093\/humrep\/deae108.041","article-title":"P-779 GLP-1 receptor agonist treatment in early pregnancy and risk of pregnancy complications\u2014a nationwide cohort study","volume":"39","author":"Hviid","year":"2024","journal-title":"Hum Reprod"},{"key":"R18-20250410","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1111\/dme.12726","article-title":"Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with type 2 diabetes","volume":"32","author":"Greco","year":"2015","journal-title":"Diabet Med"},{"key":"R19-20250410","first-page":"70","article-title":"Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report","volume":"27","author":"Ivani\u0161evi","year":"2018","journal-title":"Gynaecol Perinatol"},{"key":"R20-20250410","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2174\/0118715303252109231023115112","article-title":"Case series: exposure to glucagon-like peptide-1 receptor agonist in the first trimester of pregnancy in two siblings","volume":"24","author":"Do\u011fan","year":"2024","journal-title":"Endocr Metab Immune Disord Drug Targets"},{"key":"R21-20250410","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/TEN.0b013e3181a5875e","article-title":"Case report: exenatide use during pregnancy","volume":"19","author":"Williams","year":"2009","journal-title":"Endocrinologist"},{"key":"R22-20250410","doi-asserted-by":"crossref","first-page":"1215356","DOI":"10.3389\/fendo.2023.1215356","article-title":"Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: a systematic review of the evidence","volume":"14","author":"Muller","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R23-20250410","article-title":"Taking weight loss medication during pregnancy: is it safe?","year":"2024","journal-title":"Obes Diabetes Assoc"},{"key":"R24-20250410","doi-asserted-by":"crossref","first-page":"52.e1","DOI":"10.1016\/j.ajog.2010.02.015","article-title":"Maternal use of bupropion and risk for congenital heart defects","volume":"203","author":"Alwan","year":"2010","journal-title":"Am J Obstet Gynecol"}],"container-title":["O&amp;G Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/og9.0000000000000077","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T21:05:16Z","timestamp":1744319116000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/og9.0000000000000077"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/og9.0000000000000077","relation":{},"ISSN":["2994-9726"],"issn-type":[{"value":"2994-9726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2025-02-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}